Off-label drugs for the treatment of lupus symptoms represents the standard of care for people with lupus, but current regulations make it difficult for doctors and manufacturers to communicate. Read Sandra C. Raymond's remarks now.
When the Lupus Foundation of America became aware of a hydroxychloroquine (Plaquenil®) shortage, we set out to discover the root of problem. While we still have limited information, we want to alert our constituents to the facts of the situation.
Today’s sessions will focus on pediatric lupus and biomarkers, including a Foundation-funded research program about pediatric lupus in South Africa. Learn more!
In her Expert Column, Dr. Joan T. Merrill, Medical Director, explains why antimalarial medicines are now used to treat lupus.